How the DGT's position has evolved
Current position
Supplies, intra-Community acquisitions, and imports of products qualified as medicines for human use by the Spanish Agency of Medicines and Medical Devices are taxed at the reduced rate of 4%. If the product is not considered a medicine, the general rate of 21% applies, unless it is a pharmaceutical product from Chapter 30 of the Combined Nomenclature suitable for direct use by the final consumer, in which case it will be taxed at 10%.
The DGT's position remains constant regarding the distinction of tax rates according to the product's classification. The doctrine establishes that the status of being a medicine is the determining factor for applying the 4% rate, while the absence of such condition refers to the general rate or the 10% reduced rate for pharmaceutical products for direct use.
Analysis based on 14 of 14 rulings with a stated position. Updated 26 September 2026.